User:Psu521985/Edge Therapeutics, Inc.

Edge Therapeutics, Inc. new article content ...

Edge Therapeutics, Inc. is a specialty pharmaceutical company established in 2009 and headquartered in Newark, NJ. Edge Therapeutics, Inc. focuses on preventative treatment for secondary complications following brain injury. Edge Therapeutics, Inc. is currently developing 4 drugs. NimoGel, Edge's lead product, is being developed to prevent secondary strokes after subarachnoid hemorrhage (SAH), which is caused by bleeding into the fluid around the brain. NimoGel combines a generic calcium channel blocker nimodipine, formulated in a biodegradable polymer carrier composed of FDA-approved materials.

In 2009 Edge was awarded a $500,000 grant from the New Jersey Commission on Science and Technology Edison Innovation Fund and in 2010 Edge received $100,000 in funding from the New Jersey Economic Development Authority.